Literature DB >> 30895387

Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.

Jiali Gao1, Joanne Jones2, Erika M Damato3, Alasdair Coles2.   

Abstract

Entities:  

Keywords:  APMPPE—acute posterior multifocal placoid pigment epitheliopathy; Alemtuzumab; Autoimmunity; Multiple sclerosis

Mesh：

Substances：

Year:  2019        PMID： 30895387     DOI： 10.1007/s00415-019-09288-y

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  3 in total

1.  Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.

Authors:  Grant A Hill-Cawthorne; Tom Button; Orla Tuohy; Joanne L Jones; Karen May; Jennifer Somerfield; Alison Green; Gavin Giovannoni; D Alastair S Compston; Michael T Fahey; Alasdair J Coles
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-11-05       Impact factor: 10.154

2.  Acute posterior multifocal placoid pigment epitheliopathy.

Authors:  J D Gass
Journal:  Arch Ophthalmol       Date:  1968-08

Review 3.  Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis.

Authors:  Cristina Guarnera; Placido Bramanti; Emanuela Mazzon
Journal:  Ther Clin Risk Manag       Date:  2017-07-14       Impact factor: 2.423
  3 in total
  1 in total

Review 1.  Ocular adverse effects of therapeutic biologics.

Authors:  Helio V Neves da Silva; John Placide; Anne Duong; Yasmyne Ronquillo; Shannon McCabe; Majid Moshirfar
Journal:  Ther Adv Ophthalmol       Date:  2022-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.